ENDRA LIFE SCIENCES INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 4 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-01-02: Reporting owner Basenese Lou; Form 4; Security Stock Options; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-01-02: Reporting owner Harsh Michael; Form 4; Security Stock Options; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-01-02: Reporting owner DIGIANDOMENICO ANTHONY; Form 4; Security Stock Options; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-01-02: Reporting owner Tokman Alexander Y; Form 4; Security Stock Options; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
NDRA insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Basenese Lou Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600 600 owned after | $1.59 exercise price | $2,782.50 | 2024-02-23 |
| 2024-01-02 | Harsh Michael Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600 600 owned after | $1.59 exercise price | $2,782.50 | 2024-02-23 |
| 2024-01-02 | DIGIANDOMENICO ANTHONY Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600 600 owned after | $1.59 exercise price | $2,782.50 | 2024-02-23 |
| 2024-01-02 | Tokman Alexander Y Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600 600 owned after | $1.59 exercise price | $2,782.50 | 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| Nuwellis, Inc. (NUWE) | United States | $0.003B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B |